Abcam, ab250619, Anti-PDE1B antibody [EPR12293(2)] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal PDE1B antibody. Carrier free. Suitable for WB, IHC-P and reacts with Mouse, Rat, Human samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR12293(2),
Isotype:IgG,
Carrier free:Yes,
Reacts with:Mouse, Rat, Human,
Applications:IHC-P, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab250619 is the carrier-free version of
ab182565
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
PDE1B also known as phosphodiesterase 1B is an enzyme that importantly regulates intracellular levels of cyclic nucleotides by hydrolyzing cAMP and cGMP. With a molecular mass of approximately 66 kDa PDE1B shows a widespread tissue distribution with significant expression in the brain heart and vascular smooth muscle. The enzyme functions as a calmodulin-dependent phosphodiesterase activating in the presence of calcium levels above basal.
Biological function summary
PDE1B plays an essential role in the signaling pathways that rely on cyclic nucleotides as second messengers. It regulates calcium-mediated signal transduction affecting activities of cells such as neurons and cardiac cells. While PDE1B primarily functions as a homodimer its activity interfaces with several other cellular processes through its regulation of cyclic nucleotide concentrations modulating downstream effects.
Pathways
PDE1B acts mainly in the cAMP and cGMP signaling pathways both of which are important for cellular responses to external stimuli. It modulates the degradation of these second messengers influencing associated proteins like protein kinase A (PKA) and protein kinase G (PKG). By controlling the half-life of cAMP and cGMP PDE1B plays an important role in signal cascades that govern processes such as learning memory and blood vessel relaxation.
PDE1B has associations with neurological and cardiovascular diseases. Abnormal expression of PDE1B can contribute to conditions such as schizophrenia and hypertension. Through its involvement in cyclic nucleotide signaling PDE1B is connected to proteins like D2 dopamine receptor in schizophrenia and angiotensin II receptors in hypertension where dysregulated signaling can impact disease progression and response to treatment.